2025 · Regular session · House bill
HB3717
Explanation in preparation
Official caption: Relating to the establishment of a grant program to fund the United States Food and Drug Administration's drug development trials with ibogaine for the purpose of securing the administration's approval as a medication for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy.
Official report lists House author(s): Harris, Leach, Phelan, Orr, VanDeaver. This does not identify sponsors or amendment drafters.
Explanation pending
Official record available; a reviewed explanation has not yet been published for this bill. The caption describes its subject, not its full effect.
Read the official bill history ↗ · Official bill text ↗ · Amendments ↗
